Formula Pharmaceuticals
Oncology focused drug development company
Monday, October 17, 2011
Embassy Suites, Chesterbrook, Pennsylvania (directions)
|
About
|
Formula is a privately held, oncology focused drug development company, headquartered in the Philadelphia area. The Company's lead drug candidate, FPI-01, is a clinical development-stage immunotherapy for the treatment of various hematologic and solid tumors. A completed phase I study of FPI-01 in patients with acute myeloid leukemia (AML) demonstrated an overall survival of greater than 54 months, as compared to an expected 12 months for the current standard of care. FPI-01 was exclusively licensed by Formula in 2011 from Memorial Sloan Kettering Cancer Center (MSKCC). Operating within a virtual structure, the Company presently has a team of eight seasoned executives, and is supported by advisors who are world renowned leaders within the industry and academia.
In 2011, Formula raised approximately $1.5 million through a Series A Preferred round. The Company is currently seeking $500,000 through a convertible note, to optimally position itself for a planned $12 million Series B round and for ongoing strategic partnering discussions with large pharmaceutical companies. This note will convert into Series A Preferred stock, priced at $1.20 per share. Formula plans to raise its subsequent Series B round at $1.80 per share. This B round will fund FPI-01 through phase II stage clinical development over a 3-year period. A positive phase II clinical trial outcome represents a significant value inflection point for Formula and an exit opportunity for its investors by 2015.
Formula plans to leverage its team by developing additional drug candidates that are available through in-licensing or M&A opportunities. While such opportunities require separate capital raises, they represent potential value drivers and consecutive exit opportunities for Formula investors.
3 Major Issues
|
-
Based on the profile of Formula's investment opportunity, is there any additional information that would entice you to consider investing in Formula's convertible note offering for up to $500,000 (Series A) ? (Any additional viable angel prospect for this offering within your network?)
-
As Formula runs its $12 million Series B financing campaign, how can it best leverage its strengths/assets (including team, ongoing partnering process, ability to add more programs) for an optimal outcome of its fundraising campaign?
-
What risk-mitigating strategies should Formula consider in view of its current profile (product; team; business model; development plan; partnering plan)?
Program:
|
6:30 - Cocktails & Dinner (Cash bar and special 2-entree buffet menu)
8:00 - Maurits Geerlings MD MBA, CEO and co-founder of Formula, will deliver the Company's "Elevator" Pitch to the Group
8:20 - A Panel will address 3 Major Issues for the Company
9:00 - Open discussion: members and guests
<Top of the page>
|
 |
|
Slides
Audio
Video
Webcast
